...
首页> 外文期刊>Japanese Journal of Cancer Research >Tea polyphenol intake and changes in serum pepsinogen levels.
【24h】

Tea polyphenol intake and changes in serum pepsinogen levels.

机译:茶多酚的摄入量和血清胃蛋白酶原水平的变化。

获取原文
获取原文并翻译 | 示例

摘要

Following a phase I study, a phase II study was conducted to evaluate the effects of two different doses of tea polyphenols on serum pepsinogen levels. Subjects were patients aged 40 to 69 years who had undergone gastroscopy between 1995 and 1997 at Aichi Cancer Center Hospital, and had been found to have no disease requiring medication. Those with pepsinogen I < 70 ng/ml and pepsinogen I/II ratio < 6 were included in this study. Capsules containing 100 mg of tea polyphenols were administered for 1 year: 1 capsule per day for 101 patients (42 males and 59 females), and 6 capsules (equivalent to 10 cups) per day for 83 patients (30 males and 53 females). The enrollment of the 1 capsule group preceded that of the 6 capsule group, in which re-participation was allowed. Blood samples were obtained 1 year after participation from 86 participants of the 1 capsule group and 77 participants (43 new participants and 34 re-participants) of the 6 capsule group. The compliance in polyphenol capsule intake ranged from 11.4 to 105.7% (87.6% on average) of the scheduled amount for the 1 capsule group and 3.2 to 112.3% (77.8% on average) for the 6 capsule group. No serious polyphenol-related adverse effects were reported. The difference in pepsinogen I between before and after 1 year intake of the polyphenol was 3.1 ng/ml for the 43 participants of the 6 capsule group, but 3.5 ng/ml for the 1 capsule group. The mean pepsinogen I/II ratio for the 43 participants increased from 2.37 by 0.08. This increase was not larger than that for the 1 capsule group (from 2.61 by 0.11). Among 34 participants in both interventions, no significant increase in pepsinogen I and I/II ratio for the 6 capsule intervention was observed. This result suggests that additional polyphenol intake for 1 year in Japanese does not improve pepsinogen levels, which are considered to reflect stomach atrophy, a high-risk condition for stomach cancer.
机译:在第一阶段研究之后,进行了第二阶段研究,以评估两种不同剂量的茶多酚对血清胃蛋白酶原水平的影响。对象是年龄在40至69岁之间的患者,他们于1995年至1997年之间在爱知癌症中心医院接受了胃镜检查,没有发现需要药物治疗的疾病。胃蛋白酶原I <70 ng / ml和胃蛋白酶原I / II比<6的患者包括在本研究中。服用100毫克茶多酚的胶囊为期1年:101例患者(男性42例,女性59例)每天1粒,83例患者(男性30例,女性53例)每天6粒(相当于10杯)。第1个胶囊组的入组要比第6个胶囊组的入组要好,在第6个胶囊组中允许再次参加。参加1年后,从1个胶囊组的86名参与者和6个胶囊组的77名参与者(43名新参与者和34名再参与者)中获取了血液样本。 1个胶囊组的多酚胶囊摄入量的依从性为计划量的11.4%至105.7%(平均87.6%),而6个胶囊组的多酚胶囊摄入量的依从性为3.2至112.3%(平均77.8%)。没有严重的多酚相关不良反应的报道。 6胶囊组的43名参与者在摄入多酚1年前后之间的胃蛋白酶原I的差异为3.1 ng / ml,而1胶囊组的为3.5 ng / ml。 43名参与者的平均胃蛋白酶原I / II比值从2.37增加了0.08。这种增加不大于第一个胶囊组的增加(从2.61乘以0.11)。在这两种干预措施的34名参与者中,对于6粒胶囊干预措施,未观察到胃蛋白酶原I和I / II比率显着增加。该结果表明,日本人多摄入1年多酚不会改善胃蛋白酶原水平,这被认为反映了胃萎缩症(胃癌的高风险病状)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号